Menu
Fechar
HRS4R
Vull donar

ELISABET CUYÀS NAVARRO

Metabolisme i Càncer
Firma
ELISABET CUYÀS-NAVARRO
Posició
Investigador/a Consolidat - R3
Investigador/a Consolidat - R3
Projectes
Publicacions

Projectes

Metabolisme i Càncer

Dependencias metabólicas y regulación dietética de los puntos de control inmunitario: Nuevas dianas contra la resistencia a la inmunoterapia del cáncer

Codi oficial: PID2019-104055GB-I00 Data inici: 01/06/2020 Data fi: 31/05/2023 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINECO / Ajuda: 242,000 €
Metabolisme i Càncer

Ayuda de personal Miquel Servet

Codi oficial: CP20/00003 Data inici: 01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €

Publicacions

Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA, Lupu R

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin alpha(6)beta(1) drives endocrine resistance in breast cancer cells

Aging-Us, 2022, 14, 1200-1213 dx.doi.org/10.18632/aging.203882
0

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 2173-2188
0

Metformin and breast cancer: an opportunity for pharmacogenetics

Aging-Us, 2022, 14, 5612-5613 dx.doi.org/10.18632/aging.204180
0

Nutritional Niches of Cancer Therapy-Induced Senescent Cells

Nutrients, 2022, 14 dx.doi.org/10.3390/nu14173636
0

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23179986
0

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246101
0

Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 839-851
0

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246214

Tramonti A, Cuyàs E, Encinar JA, Pietzke M, Paone A, Verdura S, Arbusà A, Martin-Castillo B, Giardina G, Joven J, Vazquez A, Contestabile R, Cutruzzolà F, Menendez JA

Metformin Is a Pyridoxal-5 '-phosphate (PLP)-Competitive Inhibitor of SHMT2

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164009

Formulari de contacte

Coneix l’IDIBGI!

 menu